Veradermics GC awarded 144,401 stock options

Veradermics, Inc. reported that its General Counsel, Michael V. Greco, received a grant of stock options on February 3, 2026.

Rhea-AI Filing Summary

Veradermics, Inc. reported that its General Counsel, Michael V. Greco, received a grant of stock options on February 3, 2026. The award covers 144,401 stock options with an exercise price of $17 per share, held as direct beneficial ownership.

According to the vesting terms, 25% of the options vest on February 3, 2027, the first anniversary of the vesting commencement date. The remaining options vest in equal monthly installments over the following 36 months, contingent on continued service with the company.

Insider Trade Summary

Grant/Award: 144,401 shares

Grant/Award 1 txn

Insider Greco Michael V.

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	144,401	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 144,401 contracts (Direct)

Footnotes (1)

1. F1. The option vests as to 25% of the underlying shares of the Issuer's common stock, par value $0.00001 per share, on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Veradermics (MANE) report for Michael V. Greco?

Veradermics reported that General Counsel Michael V. Greco received a grant of 144,401 stock options on February 3, 2026. These options give him the right to buy Veradermics common stock at a fixed exercise price of $17 per share, subject to vesting conditions.

What are the key terms of Michael Greco’s Veradermics stock option grant?

The grant consists of 144,401 stock options with a $17 exercise price per share. Twenty-five percent of the options vest on February 3, 2027, and the remaining options vest in equal monthly installments over 36 months, contingent on his continued service with Veradermics.

How do Michael Greco’s Veradermics stock options vest over time?

The options vest using a one-year cliff followed by monthly vesting. Twenty-five percent vest on February 3, 2027, the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the next 36 months of continued service.

How many Veradermics derivative securities does Michael Greco beneficially own after this grant?

Following the transaction, Michael Greco beneficially owns 144,401 stock options in Veradermics. These are held as direct ownership and represent his entire reported derivative position from this grant, as disclosed in the Form 4 insider transaction report filed with the SEC.

Is Michael Greco’s Veradermics stock option grant classified as a buy or sell transaction?

The transaction is classified as an acquisition by grant, not a market buy or sell. The Form 4 uses transaction code “A” for a grant, award, or other acquisition, indicating the company awarded stock options as part of his compensation rather than an open-market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 07:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greco Michael V.

(Last) (First) (Middle)

C/O VERADERMICS, INCORPORATED

470 JAMES ST.

(Street)

NEW HAVEN CT 06513

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17	02/03/2026		A		144,401		(1)	02/03/2036	Common Stock	144,401	$0	144,401	D

Explanation of Responses:

1. The option vests as to 25% of the underlying shares of the Issuer's common stock, par value $0.00001 per share, on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.

Remarks:

	/s/ Michael Greco	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.